Single-use Bioreactors Market Size, Share, Growth, Trends | Report 2022-2030
The global single-use bioreactors market size was estimated at around USD 2.81 billion in 2021 and it is projected to hit around USD 12.1 billion by 2030, growing at a CAGR of 17.61% from 2022 to 2030.
Report Highlights
Owing to the rising demand for biopharmaceuticals, coupled with increasing investments in single-use technologies, the market for single-use bioreactors is expected to witness a significant growth throughout the forecast period.
Furthermore, the COVID-19 pandemic has positively impacted the market for single-use bioreactors. The race to create an effective vaccine against the SARS-CoV-2 virus is being fought by numerous biopharmaceutical firms. As a result, the need for single-use bioreactors has drastically increased. For instance, in October 2020, ABEC has supplied six 4,000 L single-use bioreactors to the Serum Institute of India, for the production of COVID-19 vaccines on a large scale at reasonable cost.
The value of the product, the time required for product development and production, and the criticality of the phase are now influencing the industry's propensity to employ single-use bioreactors. In addition, the medical industry has a significant demand for these single-use bioreactors. As a result, pharmaceutical companies use these reactors to make medicines without having to compromise on their quality. The flexibility of using single-use bioreactors is one of their main benefits. The growing trend toward multi-drug facilities necessitates the manufacture of various medications utilizing the same facility, in the shortest amount of time, and for the least amount of money. Thus, it will increase the demand for single-use bioreactors and further fuels market growth.
Additionally, the market for single-use bioreactors is anticipated to increase quickly because of considerable prospects from emerging countries, the demand for customized medicine, and an anticipated rise in biosimilar production in the U.S. For instance, around $110 billion worth of biologics is anticipated to lose their patent protection by 2020. The demand for biosimilar is therefore expected to rise in the upcoming years as a result of mounting pressure to lower healthcare costs and regulatory certainty about biosimilar and further driving the market growth.
However, the administration of single-use bioreactors-related challenges and worries about leachable and extractable are most likely to impede the market's expansion over the anticipated time. Additionally, the single-use bioreactors market is projected to benefit from new opportunities brought on by license termination and emerging markets. Despite this, the market is primarily being driven by growing SUB usage among startups and small businesses, technological developments in SUB, and the benefits offered by these products.
Additionally, SUBs have been used more frequently lately in contemporary biopharmaceutical operations. This is mainly because of its exceptional capacity to increase flexibility, decrease investment, and regulate operational expenses. Furthermore, single-use bioreactors have a wide range of uses in academic and industrial laboratories, including drug discovery, pharmaceutical, environmental, and life science research for the production of vaccines, antibodies, cell culture, and biofuels, among other things. Thus, it will increase the demand and further boost the market growth.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 2.81 billion |
| Revenue Forecast by 2030 | USD 12.1 billion |
| Growth rate from 2022 to 2030 | CAGR of 17.61% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Product, type, type of cell, molecule type, application, end-use, usage type, region |
| Companies Covered |
Sartorius Stedim Biotech; Thermo Fisher Scientific; Danaher; Merck KgaA; Celltainer Biotech BV; Getinge AB; Eppendorf AG; Cellexus; PBS Biotech Inc.; Distek Inc.; ABEC; Able Corporation & Biott Corporation; G&G Technologies Inc.; Solida Biotech GmbH; Satake Chemical Equipment Mfg., Ltd.; Stobbe Pharma GmbH; bbi-biotech GmbH |
Product Insights
The single use bioreactor systems segment captured the largest market share of over 80.03% in 2021. Single-use bioreactor systems are widely used in biopharmaceutical manufacturing processes that require high product yield. The versatility, cost-effectiveness, and high mass production capability of Single-use bioreactors would increase demand for the products leading to rapid market growth.
Furthermore, the rising demand for quick development, greater production of new bio-therapeutics including vaccines, antibodies, enzymes, and hormones, and an increase in the product quantities that can be produced in these bioreactors, contributing to the market's ongoing expansion. In addition, the increased focus of prominent manufacturers on offering small-scale bioreactors will fuel segment expansion over the next years
Type Insights
The stirred tank bioreactors segment dominated the market and accounted for the largest revenue share of 81.41% in 2021. The benefits offered by these bioreactors includes good oxygen transfer and fluid mixing ability, easy scale-up, low operating costs, compliance with cGMP requirements and alternative impellers have led to the highest penetration of stirred tank bioreactors in the market.
Additionally, the availability of wave-induced bioreactors will increase in the coming years, boosting market growth. In addition, for the past ten years, Wave Biotech AG has sold the original wave SUBs BIOSTAT RM. In 2019, the business unveiled the second version, BIOSTAT RM II, which has more sophisticated features & enhanced control of temperature and driving system. The demand for Wave-induced SUBs is anticipated to increase due to these manufacturing developments over the forecasted period. Therefore, such type of advancements by the manufacturers will drive segmental growth in the forecast period.
Type of Cell Insights
The mammalian cells segment dominated the market and accounted for the largest revenue share of 81.34% in 2021. This can be attributed to the significant penetration of this cell type in the creation of biopharmaceutical therapies and the commercial success of recombinant proteins made from mammalian cells. As per Bio Process International, 85% of biopharmaceutical candidates in clinical development are made using mammalian cell cultures.
Yeasts are dependable eukaryotic hosts for the synthesis of heterologous proteins and offer special benefits in the generation of therapeutic recombinants. The increasing attention given by numerous research organizations and scientists to the use of yeast cells in clinical or therapeutic settings will hasten market expansion during the projected timeframe. For instance, research published by NCBI in June 2021 examined cutting-edge techniques and approaches for synthesizing heterologous medicinal proteins from yeast genes
Molecule Type Insights
The vaccines segment dominated the market and accounted for the largest revenue share of 27.6% in 2021. This is majorly attributed to the COVID-19 outbreak, which has resulted in an urgent need for the development of a virus vaccine. According to Bioplan Associates, the use of single-use systems in the commercial manufacturing of vaccines is anticipated to rise sharply. Many biopharmaceutical companies are actively engaged in the quick development of COVID-19 vaccines in response to the COVID-19 pandemic.
Additionally, the growing field of cell and gene therapies is anticipated to accelerate the uptake of SUBs in this market. For instance, in January 2021, Sartorius and RoosterBio, Inc. teamed up to improve the production capabilities for gene and cell therapies. The partnership aims to increase the manufacturing of regenerative medicine. Such an ongoing and continuous increase in the adoption of single-use systems is anticipated to drive market growth.
Application Insights
In 2021, the research and development (R&D)/process development segment accounted for the largest revenue share at 77.75%. Single-use bioreactor utilization in process development is a driving force behind market expansion. For instance, according to an article published in 2020 by American Pharmaceutical Review, the industry has employed about 71.2% of single-use bioreactors for process development.
Furthermore, every component of the bioprocessing sector uses single-use systems. According to the American Pharmaceutical Review, single-use system devices are used for clinical or process development in about 85% of operations. This demonstrates the predominance of single-use bioreactors in both clinical manufacturing and R&D.
The bioproduction sector is expected to see significant use of SUBs in the near future due to the numerous benefits they provide. The widespread use of disposable reactors, from the lab to the industrial, has increased as a result of significant developments in bioreactor designs, sensor systems, and stirring motors.
Usage Type Insights
The lab-scale production segment captured the largest revenue share of 35.96% in 2021. In the biopharmaceutical business, disposable bioreactors are frequently employed in preclinical and clinical research. It is anticipated that growing single-use technology acceptance would have a substantial impact on segment growth in cell-based therapy research and vaccine production.
Throughout the projected period, it is anticipated that the large-scale production category would experience significant expansion. This is due to the quickly expanding market demand for the commercial production of biopharmaceutical goods and the growth of manufacturing capacity to accommodate these demands. For instance, Wuxi Biologics introduced a 36,000L biomanufacturing line in February 2021, employing nine 4,000L single-use bioreactors.
End-use Insights
The CMOs and CROs segment accounted for a significant revenue share of 50.02% in 2021. The demand for supply production capacity as well as quick awareness campaign change-overs is more among CMOs. As a result, they use a broader range of single-use components and systems. With the increasing trend of outsourcing, CROs & CMOs are more likely to adopt SUBs.
On the other hand, pharmaceutical and biopharmaceutical companies are estimated to witness significant growth. According to estimates, 66% of biopharmaceutical firms use disposable bioreactors in their daily operations. The market expansion was further reinforced by strategic alliances between product producers and biopharmaceutical firms. For instance, BioCentriq and Pall Corporation worked together in July 2021 to clinically manufacture Zolgensma, an FDA-approved gene therapy, utilising an iCELLis fixed bed bioreactor.
Regional Insights
North America dominated the regional market with a share of 33.65% in 2021. This is explained by the fact that the region has well-established biopharmaceutical companies and key operating players. Additionally, the region's increased production capacity has added to the market expansion. For instance, Thermo Fisher Scientific stated in September 2021 that it would build a new manufacturing facility specifically for single-use bioprocessing products.
A significant element influencing the growth of the single-use bioreactors market in the U.S. is the changing environment for manufacturing and bioprocessing. In cooperation with the Biomedical Advanced Research and Development Authority, Cytiva launched a new production facility for Xcellerex XDR single-use bioreactors in the United States in December 2020. It is a component of the company's USD 500 million worldwide manufacturing expansion plan.
Asia Pacific is estimated to witness the fastest CAGR throughout the forecast period. According to estimates, Asian businesses, including both domestic contenders and global behemoths, are building approximately half of all new bioprocessing facilities worldwide. In the near future, this is anticipated to significantly fuel market expansion in the Asia Pacific region.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Single-use Bioreactors Market, By Product Scope
7.1. Single-use Bioreactors Market, by Product Scope, 2022-2030
7.1.1. Single-use bioreactor systems
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Single-use media bags
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Single-use Filtration Assemblies
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Other Products
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Single-use Bioreactors Market, By Type
8.1. Single-use Bioreactors Market, by Type, 2022-2030
8.1.1. Stirred-tank SUBs
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Wave-induced SUBs
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Bubble-column SUBs
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Other SUBs
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Single-use Bioreactors Market, By Type of Cell
9.1. Single-use Bioreactors Market, by Type of Cell, 2022-2030
9.1.1. Mammalian Cells
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Bacterial Cells
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Yeast Cells
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Other Cells
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Single-use Bioreactors Market, By Molecule Type
10.1. Single-use Bioreactors Market, by Molecule Type, 2022-2030
10.1.1. Monoclonal Antibodies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Vaccines
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Gene Modified Cells
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Stem Cells
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Other Molecules
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Single-use Bioreactors Market, By Application
11.1. Single-use Bioreactors Market, by Application, 2022-2030
11.1.1. Research And Development (R&D) or Process Development
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Bioproduction
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Single-use Bioreactors Market, By End-use
12.1. Single-use Bioreactors Market, by End-use, 2022-2030
12.1.1. Pharmaceutical & Biopharmaceutical Companies
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. CROs & CMOs
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Academic & Research Institutes
12.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Single-use Bioreactors Market, By Usage Type
13.1. Single-use Bioreactors Market, by Usage Type, 2022-2030
13.1.1. Lab-scale Production
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Pilot-scale Production
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Large-scale Production
13.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Single-use Bioreactors Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.1.2. Market Revenue and Forecast, by Type (2017-2030)
14.1.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.1.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.1.5. Market Revenue and Forecast, by Application (2017-2030)
14.1.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.1.7. Market Revenue and Forecast, by End-use (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.1.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.1.8.7. Market Revenue and Forecast, by End-use (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.1.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.1.9.7. Market Revenue and Forecast, by End-use (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.2.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.2.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.2.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.2.7. Market Revenue and Forecast, by End-use (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.2.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.2.8.7. Market Revenue and Forecast, by End-use (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.2.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.2.9.7. Market Revenue and Forecast, by End-use (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.2.10.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.2.10.7. Market Revenue and Forecast, by End-use (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Type (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.2.11.5. Market Revenue and Forecast, by Application (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.2.11.7. Market Revenue and Forecast, by End-use (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.3.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.3.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.3.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.3.7. Market Revenue and Forecast, by End-use (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.3.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.3.8.7. Market Revenue and Forecast, by End-use (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.3.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.3.9.7. Market Revenue and Forecast, by End-use (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.3.10.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.3.10.7. Market Revenue and Forecast, by End-use (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Type (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.3.11.5. Market Revenue and Forecast, by Application (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.3.11.7. Market Revenue and Forecast, by End-use (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.4.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.4.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.4.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.4.7. Market Revenue and Forecast, by End-use (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.4.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.4.8.7. Market Revenue and Forecast, by End-use (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.4.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.4.9.7. Market Revenue and Forecast, by End-use (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.4.10.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.4.10.7. Market Revenue and Forecast, by End-use (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Type (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.4.11.5. Market Revenue and Forecast, by Application (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.4.11.7. Market Revenue and Forecast, by End-use (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.5.2. Market Revenue and Forecast, by Type (2017-2030)
14.5.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.5.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.5.5. Market Revenue and Forecast, by Application (2017-2030)
14.5.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.5.7. Market Revenue and Forecast, by End-use (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Type (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.5.8.5. Market Revenue and Forecast, by Application (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.5.8.7. Market Revenue and Forecast, by End-use (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Product Scope (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Type (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Type of Cell (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Molecule Type (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Application (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Usage Type (2017-2030)
14.5.9.7. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 15. Company Profiles
15.1. Sartorius Stedim Biotech
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Thermo Fisher Scientific
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Danaher
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Merck KgaA
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Celltainer Biotech BV
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Getinge AB
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Eppendorf AG
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Cellexus
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. PBS Biotech Inc.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Distek Inc.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers